The company will use the funds to accelerate commercialization of its brain-signal AI technology and expand its cognitive health applications.
Blood-based Biomarker for Alzheimer’s Disease Market to reach US$ 554.2 Mn by 2035 at 14.3% CAGR, driven by demand for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback